MediQuit, an Electronic Deprescribing Tool for Patients on Polypharmacy: Results of a Feasibility Study in German General Practice.
Journal
Drugs & aging
ISSN: 1179-1969
Titre abrégé: Drugs Aging
Pays: New Zealand
ID NLM: 9102074
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
accepted:
15
04
2021
pubmed:
13
7
2021
medline:
25
2
2023
entrez:
12
7
2021
Statut:
ppublish
Résumé
Deprescribing is an important task for general practitioners (GPs) in the face of risky polypharmacy. The electronic tool "MediQuit" was developed to guide GPs and patients through a deprescribing consultation that entails a drug-selection phase, shared decision making, and advice on safe implementation. A pilot study was conducted to determine the target group of patients that is selected for consultation and to assess the impact, patient involvement, and feasibility of the tool. This was an uncontrolled pilot study. GPs from two German regions were invited to use MediQuit in consultations with a view to deprescribing one drug, if appropriate. They selected patients on the basis of broad inclusion criteria. Collected data entailed participants' characteristics, patients' medication lists, deprescribed drugs, and feasibility assessments. Patients were contacted shortly after the consultation and again after 4 weeks. In total, 16 GPs agreed to participate, of whom ten actually performed deprescribing consultations. They selected 41 predominately older patients on excessive polypharmacy. Deprescribing was achieved in 70% of consultations in agreement with patients. Drugs deprescribed were symptom-lowering and preventive drugs (mainly anatomical therapeutic chemical classes A and C). GPs found MediQuit useful in initiating communication on this issue and enhancing deliberations for a deprescribing decision. The median consultation length was 15 min (interquartile range 10-20). At follow-up, GPs and patients infrequently disagreed on which drug(s) was discontinued, and GPs rated patient involvement higher than did patients themselves. MediQuit assists in identifying concrete deprescribing opportunities, patient involvement, and shared decision making. The three-step deprescribing procedure is well-accepted once initial organizational efforts are overcome. After revision, further studies are needed to enhance the quality of evidence on acceptance and effectiveness.
Sections du résumé
BACKGROUND
Deprescribing is an important task for general practitioners (GPs) in the face of risky polypharmacy. The electronic tool "MediQuit" was developed to guide GPs and patients through a deprescribing consultation that entails a drug-selection phase, shared decision making, and advice on safe implementation.
OBJECTIVES
A pilot study was conducted to determine the target group of patients that is selected for consultation and to assess the impact, patient involvement, and feasibility of the tool.
METHODS
This was an uncontrolled pilot study. GPs from two German regions were invited to use MediQuit in consultations with a view to deprescribing one drug, if appropriate. They selected patients on the basis of broad inclusion criteria. Collected data entailed participants' characteristics, patients' medication lists, deprescribed drugs, and feasibility assessments. Patients were contacted shortly after the consultation and again after 4 weeks.
RESULTS
In total, 16 GPs agreed to participate, of whom ten actually performed deprescribing consultations. They selected 41 predominately older patients on excessive polypharmacy. Deprescribing was achieved in 70% of consultations in agreement with patients. Drugs deprescribed were symptom-lowering and preventive drugs (mainly anatomical therapeutic chemical classes A and C). GPs found MediQuit useful in initiating communication on this issue and enhancing deliberations for a deprescribing decision. The median consultation length was 15 min (interquartile range 10-20). At follow-up, GPs and patients infrequently disagreed on which drug(s) was discontinued, and GPs rated patient involvement higher than did patients themselves.
DISCUSSION
MediQuit assists in identifying concrete deprescribing opportunities, patient involvement, and shared decision making. The three-step deprescribing procedure is well-accepted once initial organizational efforts are overcome. After revision, further studies are needed to enhance the quality of evidence on acceptance and effectiveness.
Identifiants
pubmed: 34251594
doi: 10.1007/s40266-021-00861-7
pii: 10.1007/s40266-021-00861-7
pmc: PMC8342343
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
725-733Informations de copyright
© 2021. The Author(s).
Références
Expert Opin Drug Saf. 2018 Dec;17(12):1185-1196
pubmed: 30540223
Br J Gen Pract. 2016 Aug;66(649):e552-60
pubmed: 27266865
BMJ Open. 2018 Jan 23;8(1):e017653
pubmed: 29362248
Br J Clin Pharmacol. 2020 Jul;86(7):1251-1266
pubmed: 32216066
J Am Geriatr Soc. 2012 Apr;60(4):616-31
pubmed: 22376048
Br J Gen Pract. 2009 Oct;59(567):721-3
pubmed: 19843420
Ther Adv Drug Saf. 2018 Jul 12;9(9):559-573
pubmed: 30181862
BMC Fam Pract. 2020 Sep 4;21(1):183
pubmed: 32887551
BMC Geriatr. 2020 Feb 12;20(1):51
pubmed: 32050899
Drugs Aging. 2019 May;36(5):481-484
pubmed: 30941728
J Am Geriatr Soc. 2020 Apr;68(4):746-753
pubmed: 32067226
J Eval Clin Pract. 2018 Apr;24(2):317-322
pubmed: 28776873
J Am Geriatr Soc. 2020 Jan;68(1):78-86
pubmed: 31509233
BMC Med. 2018 Jan 11;16(1):5
pubmed: 29321031
BMJ. 2016 Jun 03;353:i2893
pubmed: 27260319
Arch Intern Med. 2008 Feb 25;168(4):382-9
pubmed: 18299493
J Am Geriatr Soc. 2019 Sep;67(9):1843-1850
pubmed: 31250427
Eur J Hosp Pharm. 2017 Jan;24(1):43-46
pubmed: 31156897
BMC Fam Pract. 2018 Jul 9;19(1):110
pubmed: 29986668
Pharmacotherapy. 2016 Jun;36(6):694-701
pubmed: 27041466
Br J Gen Pract. 2007 Oct;57(543):777-84
pubmed: 17925134
Expert Rev Clin Pharmacol. 2020 Jan;13(1):15-22
pubmed: 31790317
Ther Adv Drug Saf. 2020 Jun 12;11:2042098620933741
pubmed: 32587680
BMJ Open. 2018 Feb 24;8(2):e017740
pubmed: 29478012
BMJ Open. 2019 Aug 15;9(8):e029954
pubmed: 31420394
BMC Fam Pract. 2012 Jul 09;13:56
pubmed: 22697490
BMC Fam Pract. 2018 Jul 28;19(1):131
pubmed: 30055583